{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:33:57Z","timestamp":1772724837083,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.xphs.2026.104165","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:08:58Z","timestamp":1768460938000},"page":"104165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comprehensive discussion on analytical method development and validation of a USP type-IV dissolution method for dexamethasone in a combination ophthalmic suspension with povidone-iodine"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1568-585X","authenticated-orcid":false,"given":"Likhit","family":"Mandal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8024-9126","authenticated-orcid":false,"given":"Praveen Kumar","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104165_bib0001","first-page":"15","article-title":"Antibiotic resistance among ocular pathogens: ARMOR surveillance 2009\u20132016","volume":"11","author":"Asbell","year":"2018","journal-title":"Clin Optom"},{"key":"10.1016\/j.xphs.2026.104165_bib0002","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ajo.2020.03.018","article-title":"Povidone-iodine and dexamethasone ophthalmic suspension for acute bacterial conjunctivitis","volume":"215","author":"Ta","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.xphs.2026.104165_bib0003","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12325-009-0062-1","article-title":"A combination povidone-iodine 0.4%\/dexamethasone 0.1% suspension in the treatment of adenoviral conjunctivitis","volume":"26","author":"Pelletier","year":"2009","journal-title":"Adv Ther"},{"key":"10.1016\/j.xphs.2026.104165_bib0004","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.survophthal.2023.11.002","article-title":"In praise of povidone-iodine application in ophthalmology","volume":"69","author":"Soleimani","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.xphs.2026.104165_bib0005","first-page":"765","article-title":"The pathology of dry eye: the interaction of the ocular surface and lacrimal glands","volume":"506","author":"Stern","year":"2002","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104165_bib0006","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104165_bib0007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1590\/S0004-27492007000100034","article-title":"Drug delivery systems for the posterior segment of the eye: fundamental basis and applications","volume":"70","author":"Fialho","year":"2007","journal-title":"Arq Bras Oftalmol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104165_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1081\/DDC-120003445","article-title":"Ocular preparations: the formulation approach","volume":"28","author":"Kaur","year":"2002","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104165_bib0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-409X(95)00012-V","article-title":"Ocular drug delivery: conventional and novel drug delivery systems","volume":"16","author":"Lang","year":"1995","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"10.1016\/j.xphs.2026.104165_bib0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.xphs.2026.104165_bib0011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00004397-197301310-00009","article-title":"The dynamics of the tear film","volume":"13","author":"Maurice","year":"1973","journal-title":"Int Ophthalmol Clin"},{"issue":"3","key":"10.1016\/j.xphs.2026.104165_bib0012","first-page":"211","article-title":"Characterization of surface-modified budesonide microparticles using X-ray photoelectron spectroscopy and inverse gas chromatography","volume":"51","author":"Steckel","year":"2001","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104165_bib0013","first-page":"424","article-title":"Preparation and characterization of hydroxypropyl methyl cellulose films containing stable nanoparticles of poorly soluble drugs","volume":"13","author":"Sievens-Figueroa","year":"2012","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.xphs.2026.104165_bib0014","first-page":"271","article-title":"Evaluation of flow-through cell dissolution method for suspension dosage form","volume":"47","author":"Adrianto","year":"2021","journal-title":"Drug Dev Ind Pharm"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2026.104165_bib0015","first-page":"357","article-title":"Formulation and evaluation of controlled release mucoadhesive microspheres of ciprofloxacin hydrochloride","volume":"529","author":"Rathore","year":"2017","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2026.104165_bib0016","first-page":"627","article-title":"In vitro dissolution profile comparison\u2014statistics and analysis of the similarity factor, f2","volume":"31","author":"Shah","year":"2014","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.xphs.2026.104165_bib0017","first-page":"867","article-title":"A randomized, controlled, multicenter study of povidone-iodine 0.6% and 5% in preoperative ocular surface disinfection","volume":"37","author":"Pepose","year":"2018","journal-title":"Cornea"},{"key":"10.1016\/j.xphs.2026.104165_bib0018","unstructured":"USP <1092>The Dissolution Procedure: Development and Validation. USP 2023."},{"key":"10.1016\/j.xphs.2026.104165_bib0019","unstructured":"USP <1220>Analytical Procedure Lifecycle. USP 2022."},{"key":"10.1016\/j.xphs.2026.104165_bib0020","unstructured":"USP <711>Dissolution. USP 2023."},{"key":"10.1016\/j.xphs.2026.104165_bib0021","unstructured":"USP <724>Drug Release. USP 2023."},{"key":"10.1016\/j.xphs.2026.104165_bib0022","series-title":"EMA Guideline on the Quality of Ophthalmic Products","year":"2022"},{"key":"10.1016\/j.xphs.2026.104165_bib0023","series-title":"Validation of Analytical Procedures: Text and Methodology","year":"2023"},{"issue":"2","key":"10.1016\/j.xphs.2026.104165_bib0024","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/cxo.13100","article-title":"Ex-vivo evaluation of the influence of pH on the ophthalmic safety, antibacterial efficacy and storage stability of povidone-iodine","volume":"104","author":"Thakur","year":"2021","journal-title":"Clin Exp Optom"},{"issue":"1","key":"10.1016\/j.xphs.2026.104165_bib0025","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1038\/s41598-024-52346-3","article-title":"Stability, homogeneity and measurement uncertainty estimation of PVP-I solutions for application on oro- and nasopharynx against SARS-CoV-2","volume":"14","author":"Moniruzzaman","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.xphs.2026.104165_bib0026","first-page":"162","article-title":"Ex-vivo evaluation of the stability, safety and antibacterial efficacy of a povidone-iodine preparation for ophthalmic use","volume":"102","author":"Lee","year":"2019","journal-title":"Clin Exp Optom"},{"issue":"2","key":"10.1016\/j.xphs.2026.104165_bib0027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.survophthal.2023.11.002","article-title":"In praise of povidone-iodine application in ophthalmology: review of adverse effects and toxicity","volume":"69","author":"Soleimani","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.xphs.2026.104165_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/chemse\/bjac006","article-title":"Taste perception of cyclic oligosaccharides: \u03b1-, \u03b2-, and \u03b3-cyclodextrins","volume":"47","author":"Martin","year":"2022","journal-title":"Chem Senses"},{"issue":"4","key":"10.1016\/j.xphs.2026.104165_bib0029","first-page":"359","article-title":"In vitro dissolution profile comparison\u2014statistics and analysis of the similarity factor, f2","volume":"22","author":"Shah","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104165_bib0030","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1208\/s12249-012-9875-3","article-title":"Using USP I and USP IV for discriminating dissolution rates of nano- and microparticle-loaded pharmaceutical strip-films","volume":"13","author":"Sievens-Figueroa","year":"2012","journal-title":"AAPS PharmSciTech"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104165_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.07.011","article-title":"A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system","volume":"321","author":"Dokoumetzidis","year":"2006","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2026.104165_bib0032","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1208\/s12249-018-1197-7","article-title":"Power of the dissolution test in distinguishing a change in dosage form critical quality attributes","volume":"19","author":"Gray","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2026.104165_bib0033","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In vitro models for the prediction of in vivo performance of oral drug formulations","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104165_bib0034","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1208\/s12249-012-9875-3","article-title":"Using USP I and USP IV for discriminating dissolution rates of nano- and microparticle-loaded pharmaceutical strip-films","volume":"13","author":"Sievens-Figueroa","year":"2012","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.xphs.2026.104165_bib0035","first-page":"24","article-title":"Power of the dissolution test in distinguishing a change in dosage form critical quality attributes","volume":"16","author":"Gray","year":"2009","journal-title":"Dissolution Technol"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104165_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.07.011","article-title":"A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system","volume":"321","author":"Dokoumetzidis","year":"2006","journal-title":"Int J Pharm"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:33:27Z","timestamp":1772721207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926000146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0022354926000146"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104165","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive discussion on analytical method development and validation of a USP type-IV dissolution method for dexamethasone in a combination ophthalmic suspension with povidone-iodine","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104165"}}